Melanophilin Inhibit the Growth and Lymph Node Metastasis of Triple Negative Breast Cancer Via the NONO-SPHK1-S1P Axis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2025 Mar 6

PMID 40050909

Authors

Xing Yao

Tan Yuen

Chen Qingchuan

Zhang Jianjun

Liu Yefu

Sun Shulan

Affiliations

Soon will be listed here.

Abstract

Background: Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis, and there are no targeted treatments available. TNBC patients are more likely to develop metastases and relapse than patients with other breast cancer subtypes. Lymph node metastasis is the first sign of metastatic spread. We aimed to characterize the mechanism of lymph node metastasis in TNBC to provide a new strategy for the treatment of TNBC.

Methods: Gene Expression Omnibus (GEO) TNBC database was utilized to screen for genes related to N staging. Screening the downstream target of Melanophilin (MLPH) in TNBC through RNA sequencing (RNA seq) analysis. Protein mass spectrometry was utilized to analyze the protein which interacts with MLPH, and RNA binding protein immunoprecipitation and quantitative real-time PCR (RIP qPCR) were utilized to verify the regulation of sphingosine kinase 1 (SPHK1) expression by MLPH through Non-POU domain-containing octamer-binding protein (NONO). Cell functional assays and in vivo models experiments further confirmed the effects of MLPH on proliferation and lymph node metastasis of TNBC through the SPHK1-S1P axis.

Results: MLPH is downregulated in TNBC and inhibits tumor growth and lymph node metastasis though the MLPH-NONO-SPHK1-S1P pathway. NONO was identified as an essential factor involved in SPHK1 mRNA splicing. MLPH interacts with NONO to inhibit SPHK1 mRNA splicing of SPHK1, which reduces the content of S1P, thereby inhibiting growth and lymph node metastasis in TNBC.

Conclusions: This study preliminarily elucidated a mechanism underlying lymph node metastasis in TNBC and identified the role of the MLPH-NONO-SPHK1-S1P axis in regulating proliferation and lymph node metastasis in TNBC. These findings may help design strategies for predicting and treating metastasis in TNBC.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Visentin B, Vekich J, Sibbald B, Cavalli A, Moreno K, Matteo R . Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-38. DOI: 10.1016/j.ccr.2006.02.023. View

Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X . RNA-binding proteins in tumor progression. J Hematol Oncol. 2020; 13(1):90. PMC: 7353687. DOI: 10.1186/s13045-020-00927-w. View

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G . Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010; 9(11):883-97. DOI: 10.1038/nrd3248. View

Gollavilli P, Kanugula A, Koyyada R, Karnewar S, Neeli P, Kotamraju S . AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. FEBS J. 2015; 282(20):3971-85. DOI: 10.1111/febs.13391. View

Yang T, Wang X, Zhou Y, Yu Q, Heng C, Yang H . SEW2871 attenuates ANIT-induced hepatotoxicity by protecting liver barrier function via sphingosine 1-phosphate receptor-1-mediated AMPK signaling pathway. Cell Biol Toxicol. 2021; 37(4):595-609. DOI: 10.1007/s10565-020-09567-9. View

Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J . NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR. Mol Ther. 2020; 29(1):291-307. PMC: 7791011. DOI: 10.1016/j.ymthe.2020.08.018. View

Tsuchida J, Nagahashi M, Takabe K, Wakai T . Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer. Mediators Inflamm. 2017; 2017:2076239. PMC: 5585627. DOI: 10.1155/2017/2076239. View

Hait N, Allegood J, Maceyka M, Strub G, Harikumar K, Singh S . Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009; 325(5945):1254-7. PMC: 2850596. DOI: 10.1126/science.1176709. View

10.

Pyne N, Pyne S . Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10(7):489-503. DOI: 10.1038/nrc2875. View

11.

Liu J, Chang X, Qian L, Chen S, Xue Z, Wu J . Proteomics-Derived Biomarker Panel Facilitates Distinguishing Primary Lung Adenocarcinomas With Intestinal or Mucinous Differentiation From Lung Metastatic Colorectal Cancer. Mol Cell Proteomics. 2024; 23(5):100766. PMC: 11092395. DOI: 10.1016/j.mcpro.2024.100766. View

12.

Mukhopadhyay S, Chatterjee A, Kogan D, Patel D, Foster D . 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. Cell Cycle. 2015; 14(20):3331-9. PMC: 4825547. DOI: 10.1080/15384101.2015.1087623. View

13.

Min S, Lee S, Woo J, Jung S, Ryu J, Yu J . Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. J Breast Cancer. 2021; 24(1):75-84. PMC: 7920868. DOI: 10.4048/jbc.2021.24.e4. View

14.

Barral D, Seabra M . The melanosome as a model to study organelle motility in mammals. Pigment Cell Res. 2004; 17(2):111-8. DOI: 10.1111/j.1600-0749.2004.00138.x. View

15.

Kolodziej M, Al Barim B, Nagl J, Weigand M, Uhl E, Uhle F . Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells. Int J Oncol. 2020; 57(4):1039-1046. DOI: 10.3892/ijo.2020.5114. View

16.

Kawai H, Osawa Y, Matsuda M, Tsunoda T, Yanagida K, Hishikawa D . Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy. Hepatology. 2021; 76(1):112-125. DOI: 10.1002/hep.32256. View

17.

Martinez-Gregorio H, Rojas-Jimenez E, Mejia-Gomez J, Diaz-Velasquez C, Quezada-Urban R, Vallejo-Lecuona F . The Evolution of Clinically Aggressive Triple-Negative Breast Cancer Shows a Large Mutational Diversity and Early Metastasis to Lymph Nodes. Cancers (Basel). 2021; 13(20). PMC: 8534164. DOI: 10.3390/cancers13205091. View

18.

Li Y, Xing Y, Wang X, Hu B, Zhao X, Zhang H . PAK5 promotes RNA helicase DDX5 sumoylation and miRNA-10b processing in a kinase-dependent manner in breast cancer. Cell Rep. 2021; 37(12):110127. DOI: 10.1016/j.celrep.2021.110127. View

19.

Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S . Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022; 15(1):121. PMC: 9422136. DOI: 10.1186/s13045-022-01341-0. View

20.

Shen M, Zhang R, Jia W, Zhu Z, Zhao L, Huang G . RNA-binding protein p54/NONO potentiates nuclear EGFR-mediated tumorigenesis of triple-negative breast cancer. Cell Death Dis. 2022; 13(1):42. PMC: 8748691. DOI: 10.1038/s41419-021-04488-9. View